NEWS
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
We are pleased to announce the successful completion of a clinical client project for Memo Therapeutics AG (MTx), Switzerland. The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients. VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met.
Press
Results of SAKK 06/14 trial with VPM1002BC
NEWS
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
Press
Results of SAKK 06/14 trial with VPM1002BC
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.
A competent partner at your side
Free first consulting session
We understand how complexe product development is, because we did it ourselves. Let us be a competent partner at your side for a secure route to a successful product.
From Bench to Product
Consulting and services
A competent partner at your side
Free first consulting session
From Bench to Product
Consulting and services
Speed up your development processes by using our expertise. We offer a comprehensive service portfolio covering all stages of pharmaceutical development.
About Vakzine Projekt Management
VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. As a client, you will benefit from the experience of our team in translational project management. This enables you to bring your development projects into clinical trials faster, more cost-effectively and with a higher probability of success.
The company was established in 2002. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.
News & Press
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
We are pleased to announce the successful completion of a clinical client project for Memo Therapeutics AG (MTx), Switzerland. The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients. VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met. Click here for more information.
Press release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases
The course of respiratory infectious disease pandemics, will strongly depend on how quickly medications or specific vaccines against the pathogens are available. Researchers wanted to investigate in a phase III trial whether the vaccine candidate VPM1002 is also protective against an infection with the novel SARS-CoV-2. The large-scale study has been carried out at several hospitals in Germany and included older people that are susceptible to severe course of the disease. Read about the results here!
VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases Including Covid-19 in the Elderly
We are pleased to announce that our VPM1002 trial, where VPM1002 was given as a prophylaxis against severe respiratory infectious diseases including COVID-19 in the elderly, has successfully been published in the journal Clinical Infectious Diseases. We could show that VPM1002 compared to placebo is reducing the days with severe respiratory disease! Read more!
